Avenzo Therapeutics has received FDA clearance for its investigational new drug application for AVZO-023, a highly selective CDK4 inhibitor with potential best-in-class properties for treating HR+/HER2- breast cancer.
Series A venture financing for epigenetic drug development has reached $342M in early 2024, marking a dramatic 375% increase from 2023 and setting a five-year record.